clonoSEQ®

NCCN Guidelines® for Acute Lymphoblastic Leukemia (ALL) in pediatric patients[1]

Diagnostic workup

Baseline characterization of leukemic clone to facilitate subsequent MRD analysis

Minimal residual disease (MRD) assessment:

- MRD is an essential component of patient evaluation over the course of sequential therapy
- If validated MRD assessment technology with appropriate sensitivity is not available locally, commercial tests are available
- Studies in both children and adults with ALL have demonstrated a strong correlation between MRD and risk for relapse, as well as prognostic significance of MRD measurements during and after initial induction therapy
- Additional MRD assessment time points should be guided by the regimen used

Reference:

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.3.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed July 29, 2021. To view the most recent and complete version of the guideline, go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use of application and disclaims any responsibility for their application or use in any way.

PM-US-cSEQ-0653